Analyst firms · Leerink Partners · FOLD
Leerink Partners FOLD price target and rating history
Amicus Therapeutics Inc. (FOLD) · Health Care
Leerink Partners rates Amicus Therapeutics Inc. (FOLD) Market Perform with a $14.50 price target, as of its latest action on Dec 29, 2025. It has published 4 rating actions on FOLD since September 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a FOLD price target in the last 12 months, the median target is $14.50. Leerink Partners's target matches it.
- Current rating
- Market Perform
- Price target
- $14.50
- Median target, all firms
- $14.50
- Actions on FOLD
- 4
Leerink Partners price target on FOLD
Every Leerink Partners rating on FOLD
- Dec 29, 2025
- Feb 24, 2022
- Jan 14, 2022
- Sep 30, 2021
How other firms rate FOLD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Jefferies | Hold | $14.50 | Jan 22, 2026 |
| Leerink Partners | Market Perform | $14.50 | Dec 29, 2025 |
| TD Cowen | Hold | $14.50 | Dec 22, 2025 |
| Citigroup | Buy | $17 | Dec 17, 2025 |
Questions about Leerink Partners and FOLD
- What is Leerink Partners's price target for FOLD?
- Leerink Partners's latest stated price target for Amicus Therapeutics Inc. (FOLD) is $14.50, from its action on Dec 29, 2025.
- What is Leerink Partners's rating on FOLD?
- Leerink Partners rates FOLD Market Perform, a neutral rating, as of Dec 29, 2025.
- When did Leerink Partners last change its view on FOLD?
- On Dec 29, 2025, Leerink Partners downgrades to Market Perform from Outperform, price target $14.50.
- How does Leerink Partners's FOLD target compare with other analysts?
- Across 4 firms with a FOLD price target in the last 12 months, the median target is $14.50. Leerink Partners's target matches it.
More FOLD rating histories
All Leerink Partners ratingsFOLD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.